Trials
24 active
59 in total · 36 in the EU
What this is
- How it works
- Calcineurin Inhibitor Immunosuppressant FDA class
- Tested for
- Age-Related Macular Degeneration
- Main trialPhase 1
- “Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult. ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under…”In the company’s words, NCT03178149 on ClinicalTrials.gov
- Other names
- FK506E · Prograf · ADVAGRAF · Astagraf XL · FK506 · MR4 · Graceptor · Prograf XL
- Given with
- Simulect (Novartis), Cellcept (Roche Palo)Other companies’ drugs in its trials
Other drugs for Age-Related Macular Degeneration
- Surabgene LomparvovecAbbVie · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
- ONS-5010Outlook Therapeutics, Inc. · Phase 3
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- Tacrolimus from EMSEMS · NCT01244659 · finished
Coming up1
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials59
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2027 | A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration | |
| Phase 4Completed | 2 Mar 2010 | A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection | |
| Phase 4Completed | 22 May 2013 | A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids | |
| Phase 4Completed | 18 Sep 2013 | A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. | |
| Phase 4Terminated | 31 Mar 2015 | A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule | |
| Phase 4Completed | 7 Nov 2015 | A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients | |
| Phase 4Terminated | 8 Apr 2016 | A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients | |
| Phase 4Completed | 22 Dec 2016 | Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation | |
| Phase 4Completed | 3 Jan 2017 | A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects | |
| Phase 4Terminated | 2 Apr 2017 | A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients | |
| Phase 4Completed | 2 May 2017 | A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome | |
| Phase 4Completed | 14 Dec 2017 | To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients | |
| Phase 4Completed | 14 Jun 2019 | To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients | |
| Phase 4Completed | Apr 2020 | Evaluate the Efficacy and Safety of the ADVAGRAF® | |
| Phase 4Completed | 16 Jun 2020 | A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) | |
| Phase 4Completed | 15 Jul 2022 | Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients | |
| Phase 3Completed | 7 Oct 2009 | Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant | |
| Phase 3Completed | 4 Jan 2013 | Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation | |
| Phase 3Completed | 11 May 2015 | Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts | |
| Phase 3Completed | 10 Sep 2018 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis | |
| Phase 2Completed | 30 Jun 2014 | A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients | |
| Phase 2Completed | 11 Dec 2020 | Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients | |
| Phase 2Completed | 21 Apr 2021 | A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time | |
| Phase 2Completed | 3 Nov 2025 | Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® | |
| Phase 2Ended | not given | A non-inferiority, randomised and controlled trial to compare the safety, tolerability and preliminary efficacy between standard and Torque Teno virus-guided immunosuppression in stable adult kidney transplant recipients with low immunological risk in the first year after transplantation | |
| Phase 3Authorised | not given | Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant recipients selected according to the AGORA algorithm for their low immunological risk and medium-term graft failure | |
| Phase 4Authorised | not given | Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients | |
| Phase 3Authorised | not given | Topical tacrolimus for the amelioration of breast cancer-related lymphedema: a randomized, double-blind, placebo-controlled phase II/III trial | |
| Phase 1Ended | not given | Assessment of the influence of the gut microbiome on tacrolimus pharmacokinetics in healthy volunteers | |
| Phase 4Authorised | not given | Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation | |
| Phase 4Authorised | not given | A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppression versus stopping immunosuppression at 6 months to safely prevent human leukocyte antigen (HLA) sensitization in patients with late renal graft failure | |
| Phase 1/2Authorised | not given | A Phase I/IIa open label single ascending dose study to assess safety and tolerability of regulatory T cells to promote discontinuation of tacrolimus monotherapy in liver transplant recipients - LiveTreg | |
| Phase 3Authorised | not given | A prospective, randomized, phase III open-label clinical trial with blinded ebd-point assessment to evaluate the efficacy and safety of cyclosporine and methoterxate in chlidren and adolescent subjects with moderate-to-severe atopic dermatitis. | |
| Phase 4Authorised | not given | Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects | |
| Phase 2Authorised | not given | A phase 2, randomized, patient and assessor blind, multicentre study comparing foetal neural stem cells transplantation to sham procedure in progressive multiple sclerosis (STEMS2) | |
| Phase 4Ended | not given | Personalized tacrolimus treatment for pediatric kidney transplant recipients by using a dosing algorithm and a once-daily tacrolimus formulation | |
| Phase 3Authorised | not given | Cyclophosphamide and Azathioprine vs Tacrolimus in antisynthetase syndrome-related interstitial lung disease : multicentric randomized phase III trial (CATR-PAT) | |
| Phase 4Ended | not given | Cognitive function after liver transplantation comparing Tacrolimus formulations | |
| Phase 3Authorised | not given | Randomised phase III, partly blinded study comparing the efficacy and safety of clobetasol, mometasone and tacrolimus in the treatment of lichen sclerosus of the vulva in a paediatric population. | |
| Phase 4Ended | not given | Evaluation of the effect of tacrolimus on carbohydrate metabolism in pre-renal transplantation dialysis patients | |
| Phase 1/2Authorised | not given | A Phase I/IIa open label single ascending dose study to investigate the safety and tolerability of regulatory T cells as an adjunctive therapy in deceased-donor kidney recipients - ProTreg | |
| Phase 1/2Authorised | not given | Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell transplantation in patients with MDS, CMML or sAML | |
| Phase 4Ended | not given | CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS | |
| Phase 4Ended | not given | Personalized Use of Resources Study (PURE) | |
| Phase 4Ended | not given | The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients. | |
| Phase 4Authorised | not given | TRANSPGx: A multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort | |
| Phase 2/3Ended | not given | A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation (Pro-Tac) | |
| Phase 4Authorised | not given | Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation | |
| Phase 4Authorised | not given | A randomized trial of tacrolimus monotherapy compared to standard triple immune suppressive medication in elderly recipients of a kidney transplant to reduce infection-related mortality and improve quality of life; the TACMONO-XL study. | |
| Phase 4Ended | not given | Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients | |
| Phase 3Ended | not given | REVOLUTION; Randomized controlled trial comparing immediate versus extended release tacrolimus; reducing calcineurin inhibitor related toxicity in lung transplantation patients | |
| Phase 4Authorised | not given | Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid with universal prophylaxis in renal recipients at high risk of post-transplant cytomegalovirus. Phase IV clinical trial (TIMTOR STUDY). | |
| Phase 4Ended | not given | Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept | |
| Phase 4Authorised | not given | Tacrolimus as prophylaxis of post-ERCP pancreatitis: a DPSG (Dutch Pancreatitis Study Group) multicenter, double-blind, randomized, placebo-controlled study. | |
| Phase 3Authorised | not given | TACITE : Impact of maintaining tacrolimus after renal transplant failure on access to a retransplantation, a randomized controlled trial | |
| Phase 4Authorised | not given | PRIMO : Precision immunosuppressive drug monitoring in liver transplantation: a randomized control trial | |
| Phase 3Authorised | not given | Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial | |
| Phase 4Authorised | not given | Influence of Antimicrobial Drugs on Mycophenolic acid and Tacrolimus Pharmacokinetics and the Gut Microbiome in Kidney Transplant Recipients (AXIS) | |
| Phase 4Authorised | not given | ACTOR – AUC Control of Tacrolimus in Organ Recipients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026